

A Functional Polymorphism in the *CHRNA3* Gene and Risk of Chronic Obstructive Pulmonary Disease in a Korean Population

Jae Yeon Lee^{1,*}, Seung Soo Yoo^{1,*},
Hyo-Gyoung Kang², Guang Jin^{2,3},
Eun Young Bae², Yi Young Choi²,
Jin Eun Choi², Hyo-Sung Jeon²,
Jaehee Lee¹, Shin Yup Lee¹,
Seung-Ick Cha¹, Chang Ho Kim¹,
and Jae Yong Park^{1,2}

¹Department of Internal Medicine, ²Department of Biochemistry and Cell Biology, Kyungpook National University School of Medicine, Daegu, Korea;
³Cancer Research Center, Yanbian University School of Basic Science, Yanji, Jilin, China

*Jae Yeon Lee and Seung Soo Yoo contributed equally to this work.

Received: 11 July 2012
Accepted: 24 October 2012

Address for Correspondence:

Jae Yong Park, MD
Departments of Internal Medicine, Kyungpook National University Medical Center, 807 Hoguk-ro, Buk-gu, Daegu 702-210, Korea
Tel: +82.53-200-2631, Fax: +82.53-200-2027
E-mail: jaeyong@knu.ac.kr

This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (Grant no. A090460).

A genome-wide association study has identified the 15q25 region as being associated with the risk of chronic obstructive pulmonary disease (COPD) in Caucasians. This study intended as a confirmatory assessment of this association in a Korean population. The rs6495309C > T polymorphism in the promoter of nicotinic acetylcholine receptor alpha subunit 3 (*CHRNA3*) gene was investigated in a case-control study that consisted of 406 patients with COPD and 394 healthy control subjects. The rs6495309 CT or TT genotype was associated with a significantly decreased risk of COPD when compared to the rs6495309 CC genotype (adjusted odds ratio = 0.69, 95% confidence interval = 0.50-0.95, $P = 0.023$). The effect of the rs6495309C > T on the risk of COPD was more evident in moderate to very severe COPD than in mild COPD under a dominant model for the variant T allele ($P = 0.024$ for homogeneity). The *CHRNA3* rs6495309C > T polymorphism on chromosome 15q25 is associated with the risk of COPD in a Korean population.

Key Words: *CHRNA3*; Pulmonary Disease, Chronic Obstructive; Polymorphism

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a disease characterized by airflow limitation that is not fully reversible (1). COPD is a major health problem worldwide, with a high rate of occurrence, and high costs with its management. It is the fourth leading cause of death in the world and the economic burdens associated with COPD is ever increasing (1, 2). Cigarette smoking is the most important risk factor for the development of COPD. Inhaled cigarette smoke induces lung inflammation by various inflammatory cells, such as neutrophil, macrophage, and CD4⁺ T cells. A variety of inflammatory mediators, such as protease, matrix metalloproteinase and tumor necrosis factor- α , can enhance lung parenchymal destruction, and cause airway remodeling. These inflammatory processes can result airway narrowing and airflow limitation, finally develops COPD (1, 3). However, only a small fraction of smokers develops symptomatic COPD, suggesting that genetic factors also contribute

to the development of COPD (4-6).

Recently, genome-wide association (GWA) studies have identified hundreds of genetic variants influencing the risk of complex human diseases, including COPD (7-9). In addition, these GWA studies have aided our understanding of diverse molecular pathways underlying specific human diseases (10, 11). The 15q25 region that contains the nicotinic acetylcholine receptor alpha subunit 5 and 3 (*CHRNA5* and *CHRNA3*) genes was initially identified as a lung cancer susceptibility locus through GWA studies conducted in Caucasian populations (12, 13). Subsequently, this 15q25 region has been reported to be also associated with risk of COPD in GWA studies (7, 14). However, the single nucleotide polymorphisms (SNPs), rs8034191 and rs1051730, identified in previous GWA studies for lung cancer and COPD in Caucasians (7-14), are extremely rare in Asians, according to HapMap data. Consistent with HapMap data, Wu et al. (15) reported that these two SNPs are very rare (minor allele frequencies < 0.05) in Chinese populations. Notably, they report

ed that among the SNPs in the *CHRNA5-CHRNA3* locus, the rs6495309C > T in the promoter of the *CHRNA3* gene affects the binding ability of the transcriptional factor, Oct-1, resulting in alteration of *CHRNA3* expression, thereby influencing lung cancer risk (15). This finding suggests that the rs6495309C > T of *CHRNA3* may be associated with the risk of COPD in Asian populations. Therefore, to verify the role of the rs6495309C > T of *CHRNA3* on the risk of COPD, we have carried out a case-control study in a Korean population.

MATERIALS AND METHODS

Study population

The patient group (n = 406) consisted of male patients who visited the respiratory center in Kyungpook National University Hospital (Daegu, Korea) between July 2006 and December 2008. Diagnosis of COPD was established by the NHLBI/WHO Global Initiative for COPD (GOLD) (1). The criteria for COPD were as follows: chronic respiratory symptoms and signs such as cough and dyspnea; post-bronchodilator forced expiratory volume at one second (FEV₁) < 80% of the predicted value, FEV₁/forced vital capacity (FVC) < 70% and FEV₁ reversibility after inhaling 200 µg salbutamol < 12% of the pre-bronchodilator FEV₁. The severity of COPD was classified by the guidelines of GOLD in terms of the percentage predicted FEV₁: mild (> 80%), moderate (50%-80%), severe (30%-50%) or very severe (< 30%). Control subjects (n = 394) were selected from a pool of healthy men who visited the general health check-up center. The enrollment criteria for the control subjects were as follows: male, age > 45 yr, current or former smoker, no known disease and no history of any disease, and no airflow limitation. All of the cases and controls were ethnic Koreans that resided in Daegu City, or in the surrounding regions. A trained interviewer completed detailed questionnaires for each patient and each control subject.

Genotyping

Genotypes of the rs6495309C > T was determined by melting-curve analysis using fluorescence labeled hybridization probes (LightCycler, Roche Diagnostic, Mannheim, Germany). A genotype success rate of greater than 99% was achieved using the LightCycler. Samples that could not be scored by the LightCycler were re-genotyped by direct sequencing using an ABI PRISM 3700 genetic analyzer (Applied Biosystems, Foster City, CA, USA). All genotyping analyses were performed "blind" with respect to the case/control status to ensure quality control. Approximately 10% of the samples were randomly selected to be genotyped again by a different investigator, and the results were 100% concordant with the original analysis.

Statistical analysis

The cases and controls were compared using the Student's t-test

for continuous variables, and a chi-squared test for categorical variables. Deviations of genotype frequencies among controls from those expected under Hardy-Weinberg equilibrium were assessed by chi-squared test (1° of freedom). Unconditional logistic regression analyses were used to calculate the odds ratio (OR) and 95% confidence interval (CI), with adjustment for possible confounders (age, and pack-years of smoking used as continuous variables). In addition to the overall association analysis, we performed a stratified analysis according to age, smoking status, and severity of COPD to explore the association between genotypes and the risk of COPD in each stratum. A homogeneity test was performed in order to compare the difference between the genotype-related ORs of the different groups. All analyses were performed using Statistical Analysis System for Windows, version 9.1 (SAS Institute, Cary, NC, USA).

Ethic statement

This study was approved by the institutional review board of the Kyungpook National University Hospital (Approval No., KNUH-BIO_10-1015). Written informed consent was obtained from each participant.

RESULTS

The baseline characteristics of the study population are shown in Table 1. There was no significant difference in the smoking status between cases and controls. Age and pack-years of smoking were significantly higher in cases than in controls (64.4 ± 7.5 vs 61.9 ± 7.9 yr, *P* < 0.001; and 43.8 ± 21.5 vs 31.7 ± 16.4 pack-yr of smoking, *P* < 0.001, respectively). These differences were controlled in the later multivariate analyses. The FEV₁ and the FEV₁/FVC ratio were significantly lower in the COPD group than in the control group (*P* < 0.001, both).

Table 2 shows the genotype distribution of rs6495309C > T among the cases and controls. The genotype distribution of the rs6495309C > T among the controls was in Hardy-Weinberg equilibrium. The frequency of the variant T allele among the

Table 1. Characteristics of the study population

Variables	Cases (n = 406)	Controls (n = 394)	<i>P</i>
Age (yr)	64.4 ± 7.5	61.9 ± 7.9	< 0.001*
Smoking status			
Former	160 (39.4) [‡]	173 (43.9)	0.197 [‡]
Current	246 (60.6)	221 (56.1)	
Pack-years	43.8 ± 21.5	31.7 ± 16.4	< 0.001*
FEV ₁ /FVC	51.7 ± 12.6	80.0 ± 7.4	< 0.001*
FEV ₁ (% Predicted)	68.4 ± 25.6	104.3 ± 16.7	
Severity			
GOLD I	154 (37.9) [‡]		
GOLD II-IV	252 (62.1)		

*t-test; [‡]Chi-square test; [‡]Numbers in parenthesis, column percentage. FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

Table 2. Distribution of the rs6495309C > T genotypes in patients with COPD and healthy controls, and the association with the risk of COPD

Genotype	Cases (n = 406)	Controls (n = 394)	P*	OR (95% CI) [†]	P [‡]	P _{trend}
CC	140 (34.5)	105 (26.6)	0.004	1.00		0.002
CT	198 (48.8)	189 (48.0)		0.79 (0.57-1.11)	0.181	
TT	68 (16.7)	100 (25.4)		0.50 (0.33-0.76)	0.001	
CC	140 (34.5)	105 (26.6)	0.016	1.00		
CT + TT	266 (65.5)	289 (73.4)		0.69 (0.50-0.95)	0.023	

*Two-sided chi-square test for genotype distributions between the cases and controls; [†]Odds ratios (ORs), 95% confidence intervals (95% CIs) and corresponding *P* values were calculated by unconditional logistic analysis, adjust for age and pack-years of smoking. COPD, Chronic obstructive lung disease.

Table 3. The associations between the rs6495309C > T genotypes and the risk of COPD according to age, smoking history, and severity of COPD

Variables	CC	CT	TT	CT + TT vs CC		P _H *
				OR (95% CI)	P	
Age (yr) [‡]						
≤ 64	67/65 [†]	90/118	28/59	0.61 (0.40-0.95)	0.027	0.483
> 64	73/40	108/71	40/41	0.77 (0.48-1.24)	0.277	
Smoking status [§]						
Former	59/48	76/79	25/46	0.65 (0.41-1.03)	0.067	0.712
Current	81/57	122/110	43/54	0.73 (0.49-1.10)	0.136	
Pack-years of smoking [§]						
≤ 32	48/54	57/112	15/58	0.47 (0.29-0.76)	0.002	0.030
> 32	92/51	141/77	53/42	0.95 (0.63-1.44)	0.798	
Severity of COPD						
GOLD I	40/105	89/189	25/100	1.07 (0.69-1.65)	0.775	0.024
GOLD II-IV	100/105	109/189	43/100	0.56 (0.39-0.80)	0.001	

**P* value for homogeneity test; [†]Number of cases/number of controls. Odds ratios (ORs), 95% confidence intervals (95% CIs) and corresponding *P* values were calculated by unconditional logistic analysis; [‡]adjusted for pack-years of smoking; [§]for age; and ^{||}for age and pack-years of smoking. COPD, Chronic obstructive lung disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

controls was 0.494, which was comparable with that (0.482) of healthy Chinese (15). The distribution of the rs6495309C > T genotypes was significantly different between the cases and controls (CC, CT, and TT genotypes; 34.5%, 48.8%, and 16.7%, respectively vs 26.6%, 48.0%, and 25.4%, respectively; *P* = 0.004), with the frequency of the variant T allele being significantly lower in the cases than in the controls (0.411 vs 0.494, *P* = 0.001). The risk of COPD decreased as the number of T alleles increased (*P*_{trend} = 0.002), and the TT genotype was associated with a significantly decreased risk of COPD when compared to the CC genotype (adjusted OR, 0.50; 95% CI, 0.33-0.76; *P* = 0.001). Individuals with the rs6495309 CT or TT genotype had a 31% (95% CI, 0.50-0.95; *P* = 0.023) decreased risk of COPD when compared to those with the rs6495309 CC genotype.

The association between the rs6495309C > T genotypes and the risk of COPD was further investigated, after stratification according to age, smoking status, and severity of COPD (Table 3). The effects of the rs6495309C > T genotype on the risk of COPD did not differ significantly between younger- and older-individuals, and former- and current-smokers (*P* value of test for homogeneity [*P*_H], both, > 0.05 in all comparisons). When stratified by the median pack-years of smoking, the effect of the rs6495309C > T genotype on the risk of COPD was more evident in lighter-smokers than in heavier-smokers under dominant model for the variant T allele (*P*_H = 0.030). When COPD cases were categorized by disease severity, the rs6495309 CT, or TT genotype

was associated with a significantly decreased risk of moderate to very severe COPD (GOLD II-IV; adjusted OR, 0.56; 95% CI, 0.39-0.80; *P* = 0.001), whereas there was no significant association between the rs6495309C > T genotypes and the risk of mild COPD (GOLD I; adjusted OR, 1.07; 95% CI, 0.69-1.65; *P*_H = 0.024).

DISCUSSION

In this study we determined the association between the rs6495309C > T polymorphism on the 15q25 region and the risk of COPD in a Korean population. The rs6495309T allele was associated with a significant decreased risk of COPD. This finding was in agreement with results of a previous GWA study which was carried out in Caucasians (7) in which the 15q25 region was a COPD susceptibility locus, thus providing strong evidence that the 15q25 region may play an important role in the development of COPD. This study is the first report of an association between the *CHRNA3* rs6495309C > T and the risk of COPD in Asians.

Acetylcholine receptors are classified into nicotinic acetylcholine receptors (nAChRs) and muscarinic receptors, and nAChRs are historically classified as neuronal- or muscle-type based on their initial site of identification and composite subunits (16). Cholinergic parasympathetic activity in the airways induces tracheobronchial smooth muscle contraction and mu-




Fig. 1. Reconstructed linkage disequilibrium (LD) plot using potentially functional single nucleotide polymorphisms with minor allele frequency $\geq 5\%$ from HapMap JPT data in the *CHRNA5/CHRNA3* locus. The black boxes indicate strong LD (confidence interval for strong LD: upper 0.98, low 0.7; fraction of strong LD in informative comparisons must be at least 0.95). The white boxes indicate strong recombination (upper confidence interval maximum 0.9). The triangles indicate haplotype blocks. The numbers in the squares are D' ($\times 100$) values. Vertical bold arrow indicates the *CHRNA3* rs6495309 location.

cous secretion (17, 18). However, there is increasing evidence that non-neuronal cholinergic systems that are found in non-neuronal cells, such as airway inflammatory cells, modulate inflammation of the lung, and thus, contribute to the development of COPD (19). It has been shown that bronchial epithelial cells, and airway fibroblasts and inflammatory cells express nAChRs (20). Nicotine and nicotine-derived nitrosamines in cigarette smoke triggers the nAChRs of inflammatory cells of the lung to release protease and oxidants that are associated with the pathogenesis of COPD (19-21). In addition, it has been demonstrated that the rs6495309T allele significantly reduces promoter activity, which in turn diminishes *CHRNA3* expression (15). Therefore, it is plausible that subjects with a lower production of rs6495309T allele for *CHRNA3* might have a lower inflammatory response to smoking exposure, thus having a decreased susceptibility to COPD.

The association between the *CHRNA3* rs6495309C > T and risk of COPD may be, in part, resulted from the fact that the SNP affects nicotinic dependence. It is known that nAChRs expressed in the key regions of the brain play an important role in controlling smoking behavior such as nicotine dependence (22-25). Several studies have reported that genetic variants of chromosome 15q25, including the *CHRNA3* rs6495309C > T, are responsible for tobacco nicotine dependence (15, 25). In the present study, however, there were no significant differences in geno-

type and allele frequencies according to smoking status and smoking exposure levels (data not shown).

Although the rs6495309 in the promoter of the *CHRNA3* gene has been reported to be a functional SNP, the association of the rs6495309 with COPD may be due to linkage disequilibrium (LD) with other functional variant(s) rather than a direct effect of the rs6495309. In order to identify the variant(s) that may be in strong LD with the rs6495309 that could be actually responsible for the alteration in COPD risk, we screened and estimated the LDs of all the potentially functional SNPs (with a minor allele frequency ≥ 0.05 in Asians) around the *CHRNA5/CHRNA3* locus including the rs6495309 using the NIEHS database (<http://manticore.niehs.nih.gov>). As shown in Fig. 1, four SNPs (rs578776, rs472054, rs660652 and rs615470) were captured. However, none of these four SNPs were in strong LD with the rs6495309 based on HapMap JPT data of the public database (<http://www.ncbi.nlm.nih.gov/SNP>). This finding suggests that the association observed in the present study may be due to direct effect of the rs6495309. However, because the four potentially functional SNPs captured from the database may also affect the risk of COPD, future studies of these four SNPs are also needed to further understand the role of genetic variants in the *CHRNA5/CHRNA3* locus in determining the risk of COPD.

In conclusion, this case-control study demonstrates a significant association of the *CHRNA3* rs6495309C > T on chromosome 15q25 with the risk of COPD. Because this is the first case-control study investigating the association of the *CHRNA3* rs6495309C > T with the risk of COPD in Asian populations, additional studies are required to confirm our findings.

REFERENCES

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary*. *Am J Respir Crit Care Med* 2007; 176: 532-55.
2. Mannino DM, Buist AS. *Global burden of COPD: risk factors, prevalence, and future trends*. *Lancet* 2007; 370: 765-73.
3. Groneberg DA, Chung KF. *Models of chronic obstructive pulmonary disease*. *Respir Res* 2004; 5: 18.
4. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. *Developing COPD: a 25 year follow up study of the general population*. *Thorax* 2006; 61: 935-9.
5. Sampsonas F, Karkoulas K, Kaparlanos A, Spiropoulos K. *Genetics of chronic obstructive pulmonary disease, beyond α 1-antitrypsin deficiency*. *Curr Med Chem* 2006; 13: 2857-73.
6. Cha SJ, Kang HG, Choi JE, Kim MJ, Park J, Lee WK, Kim CH, Jung TH, Park JY. *SERPINE2 polymorphisms and chronic obstructive pulmonary disease*. *J Korean Med Sci* 2009; 24: 1119-25.
7. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, et al. *A genome-wide association study in chronic*

- obstructive pulmonary disease (COPD): identification of two major susceptibility loci. *PLoS Genet* 2009; 5: e1000421.
8. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. *Nat Rev Genet* 2009; 10: 318-29.
 9. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. *Nat Rev Genet* 2009; 10: 241-51.
 10. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, et al. Finding the missing heritability of complex disease. *Nature* 2009; 461: 747-53.
 11. Hirschhorn JN. Genomewide association studies: illuminating biologic pathways. *N Engl J Med* 2009; 360: 1699-701.
 12. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat Genet* 2008; 40: 616-22.
 13. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* 2008; 452: 633-7.
 14. Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, Lomas DA, Silverman EK; ECLIPSE and ICGN Investigators. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010; 182: 1498-505.
 15. Wu C, Hu Z, Yu D, Huang L, Jin G, Liang J, Guo H, Tan W, Zhang M, Qian J, et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. *Cancer Res* 2009; 69: 5065-72.
 16. Caulfield MP, Birdsall NJ. International Union of Pharmacology, XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol Rev* 1998; 50: 279-90.
 17. Canning BJ. Reflex regulation of airway smooth muscle tone. *J Appl Physiol* 2006; 101: 971-85.
 18. Rogers DF. Motor control of airway goblet cells and glands. *Respir Physiol* 2001; 125: 129-44.
 19. Gwilt CR, Donnelly LE, Rogers DF. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? *Pharmacol Ther* 2007; 115: 208-22.
 20. Carlisle DL, Hopkins TM, Gaither-Davis A, Silhanek MJ, Luketich JD, Christie NA, Siegfried JM. Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. *Respir Res* 2004; 5: 27.
 21. Wessler I, Kirkpatrick CJ, Racké K. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. *Pharmacol Ther* 1998; 77: 59-79.
 22. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau O, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. *Hum Mol Genet* 2007; 16: 36-49.
 23. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, Saccone NL, Saccone SF, Bertelsen S, Fox L, et al. Variants in nicotinic receptors and risk for nicotine dependence. *Am J Psychiatry* 2008; 165: 1163-71.
 24. Li MD, Xu Q, Lou XY, Payne TJ, Niu T, Ma JZ. Association and interaction analysis of variants in *CHRNA5/CHRNA3/CHRNA4* gene cluster with nicotine dependence in African and European Americans. *Am J Med Genet B Neuropsychiatr Genet* 2010; 153B: 745-56.
 25. Jin G, Bae EY, Yang E, Lee EB, Lee WK, Choi JE, Jeon HS, Yoo SS, Lee SY, Lee J, et al. A functional polymorphism on chromosome 15q25 associated with survival of early stage non-small cell lung cancer. *J Thorac Oncol* 2012; 7: 808-14.